What New Question About Mateo Would You Investigate, and How?

Every study you read this year, from the IRF6 trios to the TOPS trial, was built on the same backbone. As a blueprint: (1) one specific testable Question; (2) a Hypothesis and what would prove you wrong; (3) the simplest Design that answers it cleanly (RCT for a treatment effect, case-control for a rare-outcome risk factor, cohort or twin for inheritance, knockout for gene function); (4) Variables, the one you change, the one you measure, what you hold constant; (5) Controls, including a comparison group; (6) Bias defense, randomize, blind, and match where you can; (7) Sample size, a power calculation before data; (8) one primary, objective, pre-defined Outcome; (9) Statistics chosen in advance, with multiple-testing correction planned; (10) Ethics, IRB or IACUC, consent and assent, the 3Rs; (11) a Report detailed enough for a stranger to repeat (CONSORT, STROBE, PRISMA, ARRIVE).

Now look at the pattern, not any one lesson. Case-parent trios found a common regulatory IRF6 risk variant that raises risk only a little, the signature of a small-effect allele, not a single broken gene. Twin and heritability designs found that clefts run partly in families, yet identical twins are often not both affected, so genes alone do not decide it. Case-control epidemiology found that environment matters too. The clinical picture is an isolated cleft, no other birth defects, no lip pits, no syndrome features. Many small genetic pushes plus environment plus chance, with no single syndrome behind it.